• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CVRx Inc.

    2/7/22 1:32:36 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care
    Get the next $CVRX alert in real time by email
    SC 13G 1 s13g_123121-cvrx.htm SCHEDULE 13G FOR CVRX, INC.

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
    (Rule 13d-102)
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    (Amendment No.   )1
     
     
    CVRx, Inc.
    (Name of Issuer)
     
     
    Common Stock, par value $0.01 per share
    (Title of Class of Securities)
     
    126638105
    (CUSIP Number)
     
     
    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)



    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [   ] Rule 13d-1(b)

    [   ] Rule 13d-1(c)

    [X] Rule 13d-1(d)



    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.  The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.





    1




    CUSIP No. 126638105


    1.
    NAME OF REPORTING PERSON
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
     
    Johnson & Johnson
    EIN:  22-1024240

    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)   [   ]
    (b)   [   ]

    3.
    SEC USE ONLY

     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION

    New Jersey




    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.
    SOLE VOTING POWER

    -0-

    6.
    SHARED VOTING POWER

    4,109,573*

    7.
    SOLE DISPOSITIVE POWER

    -0-

    8.
    SHARED DISPOSITIVE POWER

    4,109,573*

    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

    4,109,573*

    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   [   ]

     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    19.6% **

    12.
    TYPE OF REPORTING PERSON 

    CO


    * Consists of (i) 3,495,575 shares held by Johnson & Johnson Innovation-JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson, (ii)  607,725 shares issuable upon exercise of warrants to purchase Common Stock (the “Warrant Shares”) held by Biosense Webster, Inc., a wholly-owned subsidiary of Johnson & Johnson, and (iii) 6,273 shares issuable upon exercise of options to purchase Common Stock (the “Option Shares”) held by Johnson & Johnson Innovation-JJDC, Inc.
    ** Based on (i) 20,351,779 shares of Common Stock outstanding as of November 8, 2021, as reported in the Issuer’s Report on Form 10-Q for the period ended September 30, 2021 filed with the Securities and Exchange Commission on November 8, 2021 plus (ii) the Option Shares and (iii) the Warrant Shares.






    2




    CUSIP No. 126638105


    1.
    NAME OF REPORTING PERSON
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
     
    Johnson & Johnson Innovation-JJDC, Inc.
    EIN:  22-2007137

    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)   [  ]
    (b)   [  ]

    3.
    SEC USE ONLY

     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION

    New Jersey




    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.
    SOLE VOTING POWER

    -0-

    6.
    SHARED VOTING POWER

    3,501,848*

    7.
    SOLE DISPOSITIVE POWER

    -0-

    8.
    SHARED DISPOSITIVE POWER

    3,501,848*

    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

    3,501,848*

    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   [   ]

     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    17.2% **

    12.
    TYPE OF REPORTING PERSON  

    CO


    * Consists of (i) 3,495,575 shares held by Johnson & Johnson Innovation-JJDC, Inc. and (ii) 6,273 shares issuable upon exercise of options to purchase Common Stock (the “Option Shares”) held by Johnson & Johnson Innovation-JJDC, Inc.
    ** Based on (i) 20,351,779 shares of Common Stock outstanding as of November 8, 2021, as reported in the Issuer’s Report on Form 10-Q for the period ended September 30, 2021 filed with the Securities and Exchange Commission on November 8, 2021 plus (ii) the Option Shares.






    3



    CUSIP No. 126638105
    SCHEDULE 13G


    ITEM 1(a)
    NAME OF ISSUER:
       
     
    CVRx, Inc.
       
    ITEM 1(b)
    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
       
     
    9201 West Broadway Avenue, Suite 650, Minneapolis, MN  55445
       
    ITEM 2(a)
    NAME OF PERSON FILING:
       
     
    This statement is being filed by Johnson & Johnson, a New Jersey corporation (“J&J”), and Johnson & Johnson Innovation-JJDC, Inc., a New Jersey corporation (“JJDC”) (together, the Reporting Persons”).  JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are all directly beneficially owned by JJDC, with the exception of the securities that are directly beneficially owned by Biosense Webster, Inc., a wholly-owned subsidiary of J&J.  J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC and Biosense Webster, Inc.  The Joint Filing Agreement between the Reporting Persons is attached hereto as Exhibit 1.
       
    ITEM 2(b)
    ADDRESS OF PRINCIPAL BUSINESS OFFICE:
       
     
    J&J:  One Johnson & Johnson Plaza, New Brunswick, NJ 08933
    JJDC:  410 George Street, New Brunswick, NJ  08901
       
    ITEM 2(c)
    CITIZENSHIP:
       
     
    J&J: New Jersey
     
    JJDC: New Jersey
       
    ITEM 2(d)
    TITLE OF CLASS OF SECURITIES:
       
     
    Common Stock, par value $0.01 per share (“Common Stock”)
       
    ITEM 2(e)
    CUSIP NUMBER:
       
     
    126638105
       
    ITEM 3
    STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C):
       
     
    Not applicable.







    4




    CUSIP No. 126638105


    ITEM 4
    OWNERSHIP:
         
     
    The information set forth in the cover pages of this Schedule 13G is incorporated herein by reference thereto.
           
    ITEM 5
    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
     
    Not applicable.
       
    ITEM 6
    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
     
    Not applicable.
       
    ITEM 7
    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY:
       
     
    Not applicable.

    ITEM 8
    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
     
    Not applicable.
       
    ITEM 9
    NOTICE OF DISSOLUTION OF GROUP:
       
     
    Not applicable.
       
       
    ITEM 10
    CERTIFICATION:
       
     
    Not applicable.






    5




    CUSIP No. 126638105

    SIGNATURE

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated:  February 7, 2022

     
    JOHNSON & JOHNSON
     
     
     
    By:
    /s/ Matthew Orlando
     
     
    Name:
    Matthew Orlando
     
     
    Title:
    Secretary
     
           
           
     
    JOHNSON & JOHNSON INNOVATION-JJDC, INC.
     
           
     
    By:
    /s/ Sergio Calvo-Regueros
     
     
    Name:
    Sergio Calvo-Regueros
     
     
    Title:
    Assistant Treasurer
     






    6

    EXHIBIT 1

    JOINT FILING AGREEMENT

    The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit 1, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

    Dated:  February 7, 2022

     
    JOHNSON & JOHNSON
     
     
     
    By:
    /s/ Matthew Orlando
     
     
    Name:
    Matthew Orlando
     
     
    Title:
    Secretary
     
           
           
     
    JOHNSON & JOHNSON INNOVATION-JJDC, INC.
     
           
     
    By:
    /s/ Sergio Calvo-Regueros
     
     
    Name:
    Sergio Calvo-Regueros
     
     
    Title:
    Assistant Treasurer
     








    7
    Get the next $CVRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVRX

    DatePrice TargetRatingAnalyst
    5/9/2025$7.00Neutral → Underweight
    Analyst
    1/14/2025Mkt Perform → Outperform
    William Blair
    9/10/2024$14.00Overweight
    Cantor Fitzgerald
    7/11/2024$18.00 → $12.00Buy
    Lake Street
    5/1/2024$30.00 → $23.00Buy
    Craig Hallum
    5/1/2024Outperform → Mkt Perform
    William Blair
    5/1/2024$36.00 → $13.00Overweight → Neutral
    JP Morgan
    1/31/2023$20.00Buy
    Lake Street
    More analyst ratings

    $CVRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026

    MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2025 financial and operating results after market close on Thursday, Feb. 12, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone

    1/29/26 4:10:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

    MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced initiation of the BENEFIT-HF clinical trial, a landmark randomized study supported by CMS Category B IDE coverage and designed to evaluate the impact of Barostim™ in a significantly expanded heart failure population. Barostim™ is an implantable device that delivers electrical signals to baroreceptors located on the carotid artery, increasing baroreflex signaling, rebalancing the autonomic nervous system, and improving heart failure symptoms.

    1/22/26 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance

    Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5%Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11%Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11% to 18%Category I CPT codes and the related favorable physician fee payment levels took effect on Jan. 1, 2026FDA approved the BENEFIT-HF trial design in November and the Company has since applied to CMS for coverage for the trialDebt facility amended to extend maturity date to 2031 and to increase the facility from the $50 million of term loans already drawn by an additional $50 million, of which $1

    1/12/26 8:00:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Large owner Johnson & Johnson sold $224,040 worth of shares (22,337 units at $10.03) (SEC Form 4)

    4/A - CVRx, Inc. (0001235912) (Issuer)

    1/8/26 4:05:54 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Large owner Johnson & Johnson sold $63,560 worth of shares (6,337 units at $10.03) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    12/1/25 4:07:15 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Large owner Johnson & Johnson sold $10,000 worth of shares (1,000 units at $10.00) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    11/14/25 3:07:10 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CVRx Inc.

    SCHEDULE 13G/A - CVRx, Inc. (0001235912) (Subject)

    1/12/26 7:51:15 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - CVRx, Inc. (0001235912) (Filer)

    1/12/26 8:57:19 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by CVRx Inc.

    424B5 - CVRx, Inc. (0001235912) (Filer)

    1/12/26 8:45:53 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nielsen Kirk G. bought $59,795 worth of shares (10,966 units at $5.45) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/19/25 6:46:37 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Nielsen Kirk G. bought $977,346 worth of shares (187,813 units at $5.20) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/14/25 5:27:07 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $7,775 worth of shares (1,650 units at $4.71), increasing direct ownership by 49% to 5,050 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/13/25 7:12:40 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVRx, Inc. downgraded by Analyst with a new price target

    Analyst downgraded CVRx, Inc. from Neutral to Underweight and set a new price target of $7.00

    5/9/25 8:41:10 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx, Inc. upgraded by William Blair

    William Blair upgraded CVRx, Inc. from Mkt Perform to Outperform

    1/14/25 7:51:14 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on CVRx, Inc. with a new price target

    Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00

    9/10/24 7:46:21 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Leadership Updates

    Live Leadership Updates

    View All

    CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

    MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy," said Kevin Hykes, President and CEO of CVRx. "Robert is well-known and respected within the heart failure community and

    6/25/24 6:50:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

    Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition. Hykes is an accomplishe

    1/31/24 8:00:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Appoints Industry Veteran Kevin Hykes to Board of Directors

    MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) --  CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022. "We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors," said John Nehra, lead independent director of CVRx. "His commercial experience in accelerating the growth of novel interventional therapies and his executive acumen will prove an invaluable resource as we continue to build our b

    12/20/22 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Financials

    Live finance-specific insights

    View All

    CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026

    MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2025 financial and operating results after market close on Thursday, Feb. 12, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone

    1/29/26 4:10:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Reports Third Quarter 2025 Financial and Operating Results

    MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2025. Recent Highlights Total revenue for the third quarter 2025 was $14.7 million, an increase of 10% over the prior year quarterU.S. revenue for the third quarter of 2025 was $13.5 million, an increase of 10% over the prior year quarterActive implanting centers in the U.S. grew to 250, an increase of 20% since September 30, 2024CMS published the final ru

    11/5/25 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

    MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2025 financial and operating results after market close on Wednesday, Nov. 5, 2025. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, p

    10/22/25 4:30:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by CVRx Inc.

    SC 13D/A - CVRx, Inc. (0001235912) (Subject)

    11/7/24 9:10:51 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by CVRx Inc.

    SC 13G/A - CVRx, Inc. (0001235912) (Subject)

    11/1/24 11:05:15 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by CVRx Inc. (Amendment)

    SC 13G/A - CVRx, Inc. (0001235912) (Subject)

    2/6/24 7:56:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care